Comment: Nivolumab plus ipilimumab combination for advanced NSCLC

CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced melanomaПодробнее

Comment: Immunotherapy combination for advanced NSCLCПодробнее

Dr. McDermott on Nivolumab Plus Ipilimumab in RCCПодробнее

Dr. Atkinson on When to Use Nivolumab Monotherapy Versus Nivolumab/Ipilimumab CombinationПодробнее

Cemiplimab plus ipilimumab for advanced NSCLCПодробнее

CheckMate 9LA Trial on Nivolumab plus Ipilimumab for NSCLCПодробнее

CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanomaПодробнее

Nivolumab plus ipilimumab combination offers chemotherapy-free option for advanced NSCLCПодробнее

Nivolumab + Ipilimumab vs Platinum-doublet Chemotherapy as First-line Treatment for Advanced NSCLCПодробнее

Comment: Immunotherapy combo increases median survival in advanced melanomaПодробнее

CheckMate 214: patterns of progression with nivolumab plus ipilimumab versus sunitinib for RCCПодробнее

Nivolumab Plus Ipilimumab in Advanced MelanomaПодробнее

Long-Term Survival with Nivolumab + Ipilimumab in Advanced NSCLC | Dr. Sandeep Ishi | CRSF 2023Подробнее

Combination Nivolumab and Ipilimumab Shows Efficacy in Advanced MelanomaПодробнее

CheckMate 227 Induced Manageable Toxicities With Immunotherapy Combination in NSCLCПодробнее

Longterm Benefits from Nivolumab and Ipilimumab Combination TherapyПодробнее

Dr. Herbst on Combination of Nivolumab and Ipilimumab in Patients With NSCLCПодробнее

CheckMate-227: Testing Ipilimumab/Nivolumab in NSCLCПодробнее

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLCПодробнее